Published in BMC Neurosci on February 18, 2008
A self-assembling peptide acting as an immune adjuvant. Proc Natl Acad Sci U S A (2009) 1.62
Inhibition of Alzheimer's amyloid toxicity with a tricyclic pyrone molecule in vitro and in vivo. J Neurochem (2009) 1.05
Supramolecular Hydrogelators and Hydrogels: From Soft Matter to Molecular Biomaterials. Chem Rev (2015) 1.03
A cyclic undecamer peptide mimics a turn in folded Alzheimer amyloid β and elicits antibodies against oligomeric and fibrillar amyloid and plaques. PLoS One (2011) 0.78
Perspectives in molecular imaging using staging biomarkers and immunotherapies in Alzheimer's disease. ScientificWorldJournal (2013) 0.78
Evaluation of an α synuclein sensitized dendritic cell based vaccine in a transgenic mouse model of Parkinson disease. Hum Vaccin Immunother (2015) 0.77
Global antibody response to Staphylococcus aureus live-cell vaccination. Sci Rep (2016) 0.76
Dendritic and Langerhans cells respond to Aβ peptides differently: implication for AD immunotherapy. Oncotarget (2015) 0.75
Vaccination induced changes in pro-inflammatory cytokine levels as an early putative biomarker for cognitive improvement in a transgenic mouse model for Alzheimer disease. Hum Vaccin Immunother (2014) 0.75
Effect of Cinnamomum Verum Extract on the Amyloid Formation of Hen Egg-white Lysozyme and Study of its Possible Role in Alzheimer's Disease. Basic Clin Neurosci (2015) 0.75
Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 12.95
Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med (2000) 8.89
Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med (2003) 7.83
A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2001) 7.35
A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature (2001) 6.78
Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology (2003) 6.51
Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 5.60
Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology (2005) 5.51
Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron (2003) 4.39
Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science (2002) 3.93
Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. J Neurochem (2005) 3.06
Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol (2004) 3.01
Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation (2004) 2.67
Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology (2005) 2.58
Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol (2006) 2.33
Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol (2003) 2.02
T helper 1 (Th1) and Th2 characteristics start to develop during T cell priming and are associated with an immediate ability to induce immunoglobulin class switching. J Exp Med (1998) 1.91
A second-generation vaccine protects against the psychoactive effects of cocaine. Proc Natl Acad Sci U S A (2001) 1.78
Pathogenic effects of D23N Iowa mutant amyloid beta -protein. J Biol Chem (2001) 1.74
Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody. J Virol (2006) 1.71
Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants. ILAR J (2005) 1.62
Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 1.41
Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience (2006) 1.31
The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells. Int Immunol (2000) 1.28
Definition and transfer of a serological epitope specific for peptide-empty forms of MHC class I. Int Immunol (1999) 1.12
Presenile Alzheimer dementia characterized by amyloid angiopathy and large amyloid core type senile plaques in the APP 692Ala-->Gly mutation. Acta Neuropathol (1998) 0.99
Adjuvants in veterinary vaccines: modes of action and adverse effects. J Vet Intern Med (2003) 0.98
Abeta-specific T-cells reverse cognitive decline and synaptic loss in Alzheimer's mice. Neurobiol Dis (2006) 0.97
Cognitive impairment in PDAPP mice depends on ApoE and ACT-catalyzed amyloid formation. Neurobiol Aging (2004) 0.97
Effects of the amyloid precursor protein Glu693-->Gln 'Dutch' mutation on the production and stability of amyloid beta-protein. Biochem J (1999) 0.95
Mechanisms of dimethyl sulfoxide augmentation of IL-1 beta production. J Immunol (2005) 0.92
Environment- and mutation-dependent aggregation behavior of Alzheimer amyloid beta-protein. J Neurochem (2004) 0.91
Mapping of immune responses following wild-type and mutant ABeta42 plasmid or peptide vaccination in different mouse haplotypes and HLA Class II transgenic mice. Vaccine (2005) 0.90
Inflammatory pathogenesis in Alzheimer's disease: biological mechanisms and cognitive sequeli. Neurosci Biobehav Rev (1999) 0.86
A novel transcutaneous plasmid-dimethylsulfoxide delivery technique for avian nucleic acid immunization. Vet Immunol Immunopathol (2002) 0.85
Hereditary cerebral hemorrhage with amyloidosis Dutch type (AbetaPP 693): decreased plasma amyloid-beta 42 concentration. Neurobiol Dis (2003) 0.84
Inflammation and autoimmunity as a central theme in neurodegenerative disorders: fact or fiction? Curr Opin Investig Drugs (2004) 0.84
Importance of immunological and inflammatory processes in the pathogenesis and therapy of Alzheimer's disease. Int J Neurosci (1998) 0.81
JAK-STAT signaling involved in phorbol 12-myristate 13-acetate- and dimethyl sulfoxide-induced 2'-5' oligoadenylate synthetase expression in human HL-60 leukemia cells. Leuk Res (2005) 0.79
Effects of dimethyl sulfoxide on humoral immune responses to acetylcholine receptors in the rat. Clin Immunol Immunopathol (1985) 0.78
Gastritis in neonatal BALB/cCrSlc mice induced by immunization without adjuvant can be transferred to syngeneic nu/nu recipients. Scand J Immunol (2006) 0.77
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Student quality-of-life declines during third year surgical clerkship. J Surg Res (2007) 2.05
Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer's disease mice. J Alzheimers Dis (2009) 1.91
Evidence of compromised blood-spinal cord barrier in early and late symptomatic SOD1 mice modeling ALS. PLoS One (2007) 1.58
Rhabdomyolysis in the US Active Duty Army, 2004-2006. Med Sci Sports Exerc (2012) 1.52
Enrichment improves cognition in AD mice by amyloid-related and unrelated mechanisms. Neurobiol Aging (2006) 1.48
LDLR expression and localization are altered in mouse and human cell culture models of Alzheimer's disease. PLoS One (2010) 1.32
Reliability and validity of an algorithm for the diagnosis of normal cognition, mild cognitive impairment, and dementia: implications for multicenter research studies. Am J Geriatr Psychiatry (2010) 1.27
Enhanced cognitive activity--over and above social or physical activity--is required to protect Alzheimer's mice against cognitive impairment, reduce Abeta deposition, and increase synaptic immunoreactivity. Neurobiol Learn Mem (2007) 1.22
GM-CSF upregulated in rheumatoid arthritis reverses cognitive impairment and amyloidosis in Alzheimer mice. J Alzheimers Dis (2010) 1.22
Defining mild cognitive impairment: impact of varying decision criteria on neuropsychological diagnostic frequencies and correlates. Am J Geriatr Psychiatry (2010) 1.19
Pre-MCI and MCI: neuropsychological, clinical, and imaging features and progression rates. Am J Geriatr Psychiatry (2011) 1.19
Electromagnetic field treatment protects against and reverses cognitive impairment in Alzheimer's disease mice. J Alzheimers Dis (2010) 1.16
Diverse activation of microglia by chemokine (C-C motif) ligand 2 overexpression in brain. J Neuroinflammation (2013) 1.13
Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimer's disease transgenic mice. J Alzheimers Dis (2009) 1.10
Abeta-specific Th2 cells provide cognitive and pathological benefits to Alzheimer's mice without infiltrating the CNS. Neurobiol Dis (2009) 1.06
Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease. J Pineal Res (2009) 1.06
Alzheimer Abeta peptide induces chromosome mis-segregation and aneuploidy, including trisomy 21: requirement for tau and APP. Mol Biol Cell (2009) 1.04
Comparison of trait and ability measures of emotional intelligence in medical students. Med Educ (2009) 1.02
Alzheimer's presenilin 1 causes chromosome missegregation and aneuploidy. Neurobiol Aging (2006) 0.99
Cognitive impairment in PDAPP mice depends on ApoE and ACT-catalyzed amyloid formation. Neurobiol Aging (2004) 0.97
Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons. Brain (2006) 0.96
High Blood caffeine levels in MCI linked to lack of progression to dementia. J Alzheimers Dis (2012) 0.95
Alzheimer Aβ disrupts the mitotic spindle and directly inhibits mitotic microtubule motors. Cell Cycle (2011) 0.94
An investigation of PreMCI: subtypes and longitudinal outcomes. Alzheimers Dement (2012) 0.92
Caffeine synergizes with another coffee component to increase plasma GCSF: linkage to cognitive benefits in Alzheimer's mice. J Alzheimers Dis (2011) 0.92
Personal digital assistant-enabled report content knowledgebase results in more complete pathology reports and enhances resident learning. Hum Pathol (2007) 0.91
Scratch-resistant, highly conductive, and high-strength carbon nanotube-based composite yarns. ACS Nano (2010) 0.90
Volumetric and visual rating of magnetic resonance imaging scans in the diagnosis of amnestic mild cognitive impairment and Alzheimer's disease. Alzheimers Dement (2011) 0.90
Granulocyte Macrophage Colony Stimulating Factor Treatment is Associated with Improved Cognition in Cancer Patients. Brain Disord Ther (2012) 0.89
The utility of age-specific cut-offs for visual rating of medial temporal atrophy in classifying Alzheimer's disease, MCI and cognitively normal elderly subjects. Front Aging Neurosci (2013) 0.87
Minimal atrophy of the entorhinal cortex and hippocampus: progression of cognitive impairment. Dement Geriatr Cogn Disord (2011) 0.86
Green tea epigallocatechin-3-gallate (EGCG) and other flavonoids reduce Alzheimer's amyloid-induced mitochondrial dysfunction. J Alzheimers Dis (2011) 0.86
Perspectives of third-year medical students toward their surgical clerkship and a surgical career. J Surg Res (2007) 0.86
Use of multimetric statistical analysis to characterize and discriminate between the performance of four Alzheimer's transgenic mouse lines differing in Abeta deposition. Behav Brain Res (2004) 0.85
Helical Antimicrobial Sulfono-γ-AApeptides. J Med Chem (2015) 0.84
Rarity of the Alzheimer disease-protective APP A673T variant in the United States. JAMA Neurol (2015) 0.84
The cognitive change checklist (3CL): cross-validation of a measure of change in everyday cognition. Int J Geriatr Psychiatry (2010) 0.84
Mitosis-specific phosphorylation of amyloid precursor protein at threonine 668 leads to its altered processing and association with centrosomes. Mol Neurodegener (2011) 0.83
Diagnosis and staging of mild cognitive impairment, using a modification of the clinical dementia rating scale: the mCDR. Int J Geriatr Psychiatry (2010) 0.81
Caffeine increases mitochondrial function and blocks melatonin signaling to mitochondria in Alzheimer's mice and cells. Neuropharmacology (2012) 0.81
The risk for thromboembolic disease in lupus anticoagulant patients due to pathways involving P-selectin and CD154. Thromb Haemost (2007) 0.80
Mutant amyloid-beta-sensitized dendritic cells as Alzheimer's disease vaccine. J Neuroimmunol (2008) 0.79
Acupuncture-Induced Analgesia: The Role of Microglial Inhibition. Cell Transplant (2016) 0.79
Efficacy of a therapeutic vaccine using mutated β-amyloid sensitized dendritic cells in Alzheimer's mice. J Neuroimmune Pharmacol (2012) 0.79
Apolipoprotein is required for the formation of filamentous amyloid, but not for amorphous Abeta deposition, in an AbetaPP/PS double transgenic mouse model of Alzheimer's disease. J Alzheimers Dis (2004) 0.79
Sporadically occurring functional pancreatic endocrine tumors: review of recent literature. Curr Opin Oncol (2008) 0.79
Ice-assisted transfer of carbon nanotube arrays. Nano Lett (2015) 0.78
Cell therapy: a safe and efficacious therapeutic treatment for Alzheimer's disease in APP+PS1 mice. PLoS One (2012) 0.78
USE OF FUSED CIRCULATIONS TO INVESTIGATE THE ROLE OF APOLIPOPROTEIN E AS AMYLOID CATALYST AND PERIPHERAL SINK IN ALZHEIMER'S DISEASE. Technol Innov (2012) 0.78
Hippocampal neurogenesis and the brain repair response to brief stereotaxic insertion of a microneedle. Stem Cells Int (2013) 0.78
Characterization of a novel human anti-HIV-1 gp41 IgM monoclonal antibody designated clone 37. DNA Cell Biol (2004) 0.78
Evaluation of an α synuclein sensitized dendritic cell based vaccine in a transgenic mouse model of Parkinson disease. Hum Vaccin Immunother (2015) 0.77
Pap test discrepancies and follow-up histology. Diagn Cytopathol (2003) 0.77
Mitotic spindle defects and chromosome mis-segregation induced by LDL/cholesterol-implications for Niemann-Pick C1, Alzheimer's disease, and atherosclerosis. PLoS One (2013) 0.77
Pilot study of granulocyte-colony stimulating factor for treatment of Alzheimer's disease. J Alzheimers Dis (2012) 0.77
Comparing new templates and atlas-based segmentations in the volumetric analysis of brain magnetic resonance images for diagnosing Alzheimer's disease. Alzheimers Dement (2012) 0.77
Rates of ankle and foot injuries in active-duty U.S. Army soldiers, 2000-2006. Mil Med (2011) 0.76
Brain-derived Neurotrophic Factor Signaling Pathway: Modulation by Acupuncture in Telomerase Knockout Mice. Altern Ther Health Med (2015) 0.76
Medical student quality-of-life in the clerkships: a scale validation study. Am Surg (2015) 0.76
Overcoming diverse security protocols across institutions to enable convenient file-sharing and videoconferencing among collaborators. AMIA Annu Symp Proc (2005) 0.75
Response to letter "Quality of life is not quality of clerkship". J Surg Res (2009) 0.75
A novel technique for simultaneous bilateral brain infusions in a mouse model of neurodegenerative disease. J Neurosci Methods (2009) 0.75
A second case report of lleuprolide acetate for depot suspension-induced mania. CNS Spectr (2010) 0.75
Psychometrics of Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) scores. Psychol Rep (2011) 0.75
Thermoacoustic chips with carbon nanotube thin yarn arrays. Nano Lett (2013) 0.75
Invasive cutaneous verruco-cystic squamous cell carcinoma. A pattern commonly present in transplant recipients. Am J Clin Pathol (2003) 0.75
Rates of knee injury in the U.S. Active Duty Army, 2000-2005. Mil Med (2012) 0.75
A study of results generated using the Abbott LCx-GC assay fails to reveal a performance-based rationale for the 2002 level 1 recall. Am J Clin Pathol (2005) 0.75
Use of artificial neural networks to determine cognitive impairment and therapeutic effectiveness in Alzheimer's transgenic mice. J Neurosci Methods (2007) 0.75
Cross-validation of the Florida Cognitive Activities Scale (FCAS) in an Alzheimer's disease research center sample. J Geriatr Psychiatry Neurol (2009) 0.75